Abiopharma

Alpha Cognition is a biopharmaceutical company dedicated to developing treatments for patients with neurodegenerative diseases. On July 26, 2024, the Company received FDA approval for the Companys New Drug Application (the NDA) for ZUNVEYL® (benzgalantamine) oral tablet for the treatment of mild-to-moderate Alzheimers disease. The Companys focus is on the development of commercial manufacturing and sales of ZUNVEYL. The Company has three additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimers disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal (ALPHA-1062IN) formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI; otherwise known as concussion) and Progranulin GEMs, for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis.

Additional info from NASDAQ:
Alpha Cognition is a biopharmaceutical company dedicated to developing treatments for patients with neurodegenerative diseases. On July 26, 2024, the Company received FDA approval for the Companys New Drug Application (the NDA) for ZUNVEYL® (benzgalantamine) oral tablet for the treatment of mild-to-moderate Alzheimers disease. The Companys focus is on the development of commercial manufacturing and sales of ZUNVEYL. The Company has three additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimers disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal (ALPHA-1062IN) formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI; otherwise known as concussion) and Progranulin GEMs, for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis.